Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
Identifieur interne : 000491 ( Main/Exploration ); précédent : 000490; suivant : 000492Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
Auteurs : Gaurav Joshi [Inde] ; Shikha Thakur [Inde] ; Mayank [Inde] ; Ramarao Poduri [Inde]Source :
- Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [ 1873-6351 ] ; 2021.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Antiviraux, Chloroquine, Hydroxychloroquine.
- usage thérapeutique : Antiviraux, Chloroquine, Hydroxychloroquine.
- Animaux, Humains, Pandémies.
English descriptors
- KwdEn :
- Animals (MeSH), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (prevention & control), Chloroquine (adverse effects), Chloroquine (therapeutic use), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Pandemics (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Chloroquine, Hydroxychloroquine.
- drug therapy : COVID-19.
- prevention & control : COVID-19.
- Animals, Humans, Pandemics.
Abstract
The review summarizes chloroquine (CQ) and its safer derivative hydroxychloroquine (HCQ) and its utility in Covid-19. Recently this well-established drug made its way back to the headlines during the SARS-CoV-2 pandemic. This led to an upsurge in the scientific arena with multiple research and review articles along with expert opinions and commentaries. The HCQ has received mixed judgements so far about its efficacy to be used in Covid-19 patients in a limited trial conducted all across the Globe. The purpose of our article is to put forth the history, pharmacodynamics, and pharmacokinetics, along with the existing studies favouring and disapproving the role of HCQ in the treatment of Covid-19. We grouped HCQ use at three stages, this includes HCQ for i. prophylactic use by asymptomatic health workers or peoples at higher risk; ii. patients having mild symptoms; iii. patients with extreme symptoms. The review critically discusses the underlying plausible reasons and mechanisms exploring HCQ in prophylactic management or treatment of SARS-CoV-2. Furthermore, we have critically analysed the reported pharmacokinetic parameters and compiled the proponent, opponent, or neutral opinions on the use of HCQ in Covid-19. Authors discretion is to conduct more studies considering the optimal dosing regimen and pharmacokinetics assessment.
DOI: 10.1016/j.fct.2021.112106
PubMed: 33722600
PubMed Central: PMC7959684
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.</title><author><name sortKey="Joshi, Gaurav" sort="Joshi, Gaurav" uniqKey="Joshi G" first="Gaurav" last="Joshi">Gaurav Joshi</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, 248002, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: garvpharma29@gmail.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, 248002, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001</wicri:regionArea><wicri:noRegion>151001</wicri:noRegion></affiliation></author><author><name sortKey="Thakur, Shikha" sort="Thakur, Shikha" uniqKey="Thakur S" first="Shikha" last="Thakur">Shikha Thakur</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001</wicri:regionArea><wicri:noRegion>151001</wicri:noRegion></affiliation></author><author><name sortKey="Mayank" sort="Mayank" uniqKey="Mayank" last="Mayank">Mayank</name><affiliation wicri:level="1"><nlm:affiliation>Shobhaben Pratapbhai Patel - School of Pharmacy & Technology Management, SVKM's NMIMS University, Vile Parle, Mumbai, 400056, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Shobhaben Pratapbhai Patel - School of Pharmacy & Technology Management, SVKM's NMIMS University, Vile Parle, Mumbai, 400056</wicri:regionArea><wicri:noRegion>400056</wicri:noRegion></affiliation></author><author><name sortKey="Poduri, Ramarao" sort="Poduri, Ramarao" uniqKey="Poduri R" first="Ramarao" last="Poduri">Ramarao Poduri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: ramaraop@yahoo.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001</wicri:regionArea><wicri:noRegion>151001</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33722600</idno><idno type="pmid">33722600</idno><idno type="doi">10.1016/j.fct.2021.112106</idno><idno type="pmc">PMC7959684</idno><idno type="wicri:Area/Main/Corpus">000234</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000234</idno><idno type="wicri:Area/Main/Curation">000234</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000234</idno><idno type="wicri:Area/Main/Exploration">000234</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.</title><author><name sortKey="Joshi, Gaurav" sort="Joshi, Gaurav" uniqKey="Joshi G" first="Gaurav" last="Joshi">Gaurav Joshi</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, 248002, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: garvpharma29@gmail.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, 248002, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001</wicri:regionArea><wicri:noRegion>151001</wicri:noRegion></affiliation></author><author><name sortKey="Thakur, Shikha" sort="Thakur, Shikha" uniqKey="Thakur S" first="Shikha" last="Thakur">Shikha Thakur</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001</wicri:regionArea><wicri:noRegion>151001</wicri:noRegion></affiliation></author><author><name sortKey="Mayank" sort="Mayank" uniqKey="Mayank" last="Mayank">Mayank</name><affiliation wicri:level="1"><nlm:affiliation>Shobhaben Pratapbhai Patel - School of Pharmacy & Technology Management, SVKM's NMIMS University, Vile Parle, Mumbai, 400056, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Shobhaben Pratapbhai Patel - School of Pharmacy & Technology Management, SVKM's NMIMS University, Vile Parle, Mumbai, 400056</wicri:regionArea><wicri:noRegion>400056</wicri:noRegion></affiliation></author><author><name sortKey="Poduri, Ramarao" sort="Poduri, Ramarao" uniqKey="Poduri R" first="Ramarao" last="Poduri">Ramarao Poduri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: ramaraop@yahoo.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001</wicri:regionArea><wicri:noRegion>151001</wicri:noRegion></affiliation></author></analytic><series><title level="j">Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</title><idno type="eISSN">1873-6351</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (prevention & control)</term><term>Chloroquine (adverse effects)</term><term>Chloroquine (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Chloroquine (effets indésirables)</term><term>Chloroquine (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Pandémies (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The review summarizes chloroquine (CQ) and its safer derivative hydroxychloroquine (HCQ) and its utility in Covid-19. Recently this well-established drug made its way back to the headlines during the SARS-CoV-2 pandemic. This led to an upsurge in the scientific arena with multiple research and review articles along with expert opinions and commentaries. The HCQ has received mixed judgements so far about its efficacy to be used in Covid-19 patients in a limited trial conducted all across the Globe. The purpose of our article is to put forth the history, pharmacodynamics, and pharmacokinetics, along with the existing studies favouring and disapproving the role of HCQ in the treatment of Covid-19. We grouped HCQ use at three stages, this includes HCQ for i. prophylactic use by asymptomatic health workers or peoples at higher risk; ii. patients having mild symptoms; iii. patients with extreme symptoms. The review critically discusses the underlying plausible reasons and mechanisms exploring HCQ in prophylactic management or treatment of SARS-CoV-2. Furthermore, we have critically analysed the reported pharmacokinetic parameters and compiled the proponent, opponent, or neutral opinions on the use of HCQ in Covid-19. Authors discretion is to conduct more studies considering the optimal dosing regimen and pharmacokinetics assessment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33722600</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-6351</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title><ISOAbbreviation>Food Chem Toxicol</ISOAbbreviation></Journal><ArticleTitle>Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.</ArticleTitle><Pagination><MedlinePgn>112106</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0278-6915(21)00139-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fct.2021.112106</ELocationID><Abstract><AbstractText>The review summarizes chloroquine (CQ) and its safer derivative hydroxychloroquine (HCQ) and its utility in Covid-19. Recently this well-established drug made its way back to the headlines during the SARS-CoV-2 pandemic. This led to an upsurge in the scientific arena with multiple research and review articles along with expert opinions and commentaries. The HCQ has received mixed judgements so far about its efficacy to be used in Covid-19 patients in a limited trial conducted all across the Globe. The purpose of our article is to put forth the history, pharmacodynamics, and pharmacokinetics, along with the existing studies favouring and disapproving the role of HCQ in the treatment of Covid-19. We grouped HCQ use at three stages, this includes HCQ for i. prophylactic use by asymptomatic health workers or peoples at higher risk; ii. patients having mild symptoms; iii. patients with extreme symptoms. The review critically discusses the underlying plausible reasons and mechanisms exploring HCQ in prophylactic management or treatment of SARS-CoV-2. Furthermore, we have critically analysed the reported pharmacokinetic parameters and compiled the proponent, opponent, or neutral opinions on the use of HCQ in Covid-19. Authors discretion is to conduct more studies considering the optimal dosing regimen and pharmacokinetics assessment.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, 248002, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: garvpharma29@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakur</LastName><ForeName>Shikha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayank</LastName><AffiliationInfo><Affiliation>Shobhaben Pratapbhai Patel - School of Pharmacy & Technology Management, SVKM's NMIMS University, Vile Parle, Mumbai, 400056, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poduri</LastName><ForeName>Ramarao</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151001, India. Electronic address: ramaraop@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Food Chem Toxicol</MedlineTA><NlmUniqueID>8207483</NlmUniqueID><ISSNLinking>0278-6915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chloroquine</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Toxicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33722600</ArticleId><ArticleId IdType="pii">S0278-6915(21)00139-3</ArticleId><ArticleId IdType="doi">10.1016/j.fct.2021.112106</ArticleId><ArticleId IdType="pmc">PMC7959684</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Joshi, Gaurav" sort="Joshi, Gaurav" uniqKey="Joshi G" first="Gaurav" last="Joshi">Gaurav Joshi</name></noRegion><name sortKey="Mayank" sort="Mayank" uniqKey="Mayank" last="Mayank">Mayank</name><name sortKey="Poduri, Ramarao" sort="Poduri, Ramarao" uniqKey="Poduri R" first="Ramarao" last="Poduri">Ramarao Poduri</name><name sortKey="Thakur, Shikha" sort="Thakur, Shikha" uniqKey="Thakur S" first="Shikha" last="Thakur">Shikha Thakur</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000491 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000491 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33722600
|texte= Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33722600" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |